Effects of Liraglutide as Add-on to Metformin on Hepatic Steatosis and Fibrosis in Patients with Prediabetes and MASLD: A Retrospective Cohort Study

Background and Aims: The coexistence of prediabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) is common and accelerates metabolic and hepatic complications. This study evaluated the effects of liraglutide on hepatic steatosis and fibrosis in patients with prediabetes and MASLD. Methods: This retrospective cohort study included 263 patients with prediabetes and MASLD who received either liraglutide plus metformin (liraglutide group, n=142) or metformin alone (control group, n=121) for 12 months. Primary outcomes were changes in controlled attenuation parameter (CAP), liver stiffness measurement (LSM), Fibrosis-4 (FIB-4) index, and non-alcoholic fatty liver disease fibrosis score (NFS). Secondary outcomes included anthropometric measurements, glycemic parameters, lipid profiles, and liver enzymes. Results: After 12 months of treatment, CAP values decreased significantly in both groups (both p<0.001), with significantly lower values in the liraglutide group compared to the control group (p<0.001). LSM showed significant reductions in both groups, with more pronounced improvement in the liraglutide group (p<0.001) and significantly lower values compared to the control group at 12 months (p<0.05). FIB-4 index and NFS decreased significantly in both groups (p<0.05), though between-group differences did not reach statistical significance (p>0.05). The liraglutide group achieved significantly greater improvements in body weight, waist circumference, glycemic parameters [fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR)], triglycerides, and non-high-density lipoprotein (HDL) cholesterol compared to the control group (all p<0.05). Liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST]), gamma-glutamyl transferase (GGT)] improved significantly in both groups, with greater reductions in the liraglutide group (all p<0.001). The most common adverse events were mild-to-moderate gastrointestinal symptoms, with no serious adverse events reported. Conclusions: In patients with prediabetes and MASLD, 12-month liraglutide as add-on therapy to metformin was associated with significant improvements in hepatic steatosis and liver stiffness measurement compared to metformin monotherapy, alongside favorable metabolic effects and an acceptable safety profile. These findings support liraglutide as a potential therapeutic option for this high-risk population.

Authors

Institutions

Publication Details

Journal
Journal of Gastrointestinal and Liver Diseases
Published
2026-11-21
DOI
https://doi.org/10.15403/jgld-6926
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effects of Liraglutide as Add-on to Metformin on Hepatic Steatosis and Fibrosis in Patients with Prediabetes and MASLD: A Retrospective Cohort Study

Renmin Tang, Qin He, Jianming Yang, Wen Wang
Journal of Gastrointestinal and Liver Diseases
Liver Disease Diagnosis and Treatment
article

Effects of Liraglutide as Add-on to Metformin on Hepatic Steatosis and Fibrosis in Patients with Prediabetes and MASLD: A Retrospective Cohort Study

Renmin Tang, Qin He, Jianming Yang, Wen Wang
article en

Abstract

Background and Aims: The coexistence of prediabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) is common and accelerates metabolic and hepatic complications. This study evaluated the effects of liraglutide on hepatic steatosis and fibrosis in patients with prediabetes and MASLD. Methods: This retrospective cohort study included 263 patients with prediabetes and MASLD who received either liraglutide plus metformin (liraglutide group, n=142) or metformin alone (control group, n=121) for 12 months. Primary outcomes were changes in controlled attenuation parameter (CAP), liver stiffness measurement (LSM), Fibrosis-4 (FIB-4) index, and non-alcoholic fatty liver disease fibrosis score (NFS). Secondary outcomes included anthropometric measurements, glycemic parameters, lipid profiles, and liver enzymes. Results: After 12 months of treatment, CAP values decreased significantly in both groups (both p<0.001), with significantly lower values in the liraglutide group compared to the control group (p<0.001). LSM showed significant reductions in both groups, with more pronounced improvement in the liraglutide group (p<0.001) and significantly lower values compared to the control group at 12 months (p<0.05). FIB-4 index and NFS decreased significantly in both groups (p<0.05), though between-group differences did not reach statistical significance (p>0.05). The liraglutide group achieved significantly greater improvements in body weight, waist circumference, glycemic parameters [fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR)], triglycerides, and non-high-density lipoprotein (HDL) cholesterol compared to the control group (all p<0.05). Liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST]), gamma-glutamyl transferase (GGT)] improved significantly in both groups, with greater reductions in the liraglutide group (all p<0.001). The most common adverse events were mild-to-moderate gastrointestinal symptoms, with no serious adverse events reported. Conclusions: In patients with prediabetes and MASLD, 12-month liraglutide as add-on therapy to metformin was associated with significant improvements in hepatic steatosis and liver stiffness measurement compared to metformin monotherapy, alongside favorable metabolic effects and an acceptable safety profile. These findings support liraglutide as a potential therapeutic option for this high-risk population.

Journal of Gastrointestinal and Liver Diseases
Yichang Central People's Hospital (CN)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon